The short version of visceral adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
The two-fold purpose of the double-lumen technology was: (i) the aesthetic benefits of silicone gel (contained in the inner lumen) that is enclosed within the outer lumen, which is filled with saline solution; and (ii) a breast prosthesis whose volume is post-operatively adjustable. In surgical practise, the double-lumen prosthetic breast is used primarily in reconstructive surgery of the breasts.
Sickle cell disease (SCD), also simply called sickle cell, is a group of inherited hemoglobin-related blood disorders. Sickle cell disease is caused by an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to the red blood cells adopting an abnormal sickle-like shape under certain circumstances. With this shape, they cannot deform as they pass through capillaries, causing blockages. Problems in sickle cell disease typically begin around 5 to 6 months of age. Several health problems may develop, such as attacks of pain (known as a sickle cell crisis) in joints, anaemia, swelling in the hands and feet, bacterial infections, dizziness and stroke. The probability of severe symptoms, including long-term pain, increases with age. Without treatment, people with sickle cell disease rarely reach adulthood, but with good healthcare, median life expectancy is between 58 and 66 years. All of the major organs are affected by sickle cell disease. The liver, heart, kidneys, lungs, gallbladder, eyes, bones, and joints can be damaged by abnormal sickle cells and their inability to flow through the small blood vessels. Sickle cell disease occurs when a person inherits two abnormal copies of the β-globin gene that make haemoglobin, one from each parent. The abnormal gene generates haemoglobin S (HbS) which changes the properties of red blood cells.
==== Evolutionary covariation to predict 3D contacts ==== As sequencing became more commonplace in the 1990s several groups used protein sequence alignments to predict correlated mutations and it was hoped that these coevolved residues could be used to predict tertiary structure (using the analogy to distance constraints from experimental procedures such as NMR). The assumption is when single residue mutations are slightly deleterious, compensatory mutations may occur to restabilize residue-residue interactions. This early work used what are known as local methods to calculate correlated mutations from protein sequences, but suffered from indirect false correlations which result from treating each pair of residues as independent of all other pairs. In 2011, a different, and this time global statistical approach, demonstrated that predicted coevolved residues were sufficient to predict the 3D fold of a protein, providing there are enough sequences available (>1,000 homologous sequences are needed). The method, EVfold, uses no homology modeling, threading or 3D structure fragments and can be run on a standard personal computer even for proteins with hundreds of residues. The accuracy of the contacts predicted using this and related approaches has now been demonstrated on many known structures and contact maps, including the prediction of experimentally unsolved transmembrane proteins.
{\displaystyle u(r,t)={\frac {G}{4\mu }}\left(R^{2}-r^{2}\right)+[\alpha F_{2}+\beta (F_{1}-1)]{\frac {\cos \omega t}{\rho \omega }}+[\beta F_{2}-\alpha (F_{1}-1)]{\frac {\sin \omega t}{\rho \omega }}}
Sources: en.wikipedia.org
== History == The idea of recombinant DNA was first proposed by Peter Lobban, a graduate student of Prof. Dale Kaiser in the Biochemistry Department at Stanford University Medical School. The first publications describing the successful production and intracellular replication of recombinant DNA appeared in 1972 and 1973, from Stanford and UCSF. In 1980 Paul Berg, a professor in the Biochemistry Department at Stanford and an author on one of the first papers was awarded the Nobel Prize in Chemistry for his work on nucleic acids "with particular regard to recombinant DNA". Werner Arber, Hamilton Smith, and Daniel Nathans shared the 1978 Nobel Prize in Physiology or Medicine for the discovery of restriction endonucleases which enhanced the techniques of rDNA technology. Stanford University applied for a U.S. patent on recombinant DNA on November 4, 1974, listing the inventors as Herbert W. Boyer (professor at the University of California, San Francisco) and Stanley N. Cohen (professor at Stanford University); this patent, U.S. 4,237,224A, was awarded on December 2, 1980. The first licensed drug generated using recombinant DNA technology was human insulin, developed by Genentech and licensed by Eli Lilly and Company.
Subsequent activation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-aspartate) and kainate subtypes of ionotropic glutamate receptors follows. It is the activation of these receptors that potentiates the pain signal up the spinal cord. This idea, although true, is an oversimplification of pain transduction. A litany of other neurotransmitter and neuromodulators, such as calcitonin gene-related peptide (CGRP), adenosine triphosphate (ATP), brain-derived neurotrophic factor (BDNF), somatostatin, vasoactive intestinal peptide (VIP), galanin, and vasopressin are all synthesized and released in response to noxious stimuli. In addition to each of these regulatory factors, several other interactions between pain-transmitting neurons and other neurons in the dorsal horn have added impact on pain pathways.
Edgar Degas's 1876 painting The Absinthe Drinker or Glass of Absinthe (L'Absinthe) can be seen at the Musée d'Orsay epitomising the popular view of absinthe addicts as sodden and benumbed, and Émile Zola described its effects in his novel L'Assommoir. In 1905, Swiss farmer Jean Lanfray murdered his wife and two children and then attempted to kill himself after drinking absinthe. Lanfray had drunk a lot of wine and brandy before the killings, but that was overlooked or ignored, and blame for the murders was placed solely on his consumption of two glasses of absinthe. The Lanfray murders were the tipping point in this hotly debated topic, and a subsequent petition collected more than 82,000 signatures to ban it in Switzerland. A referendum was held on 5 July 1908. It was approved by voters, and the prohibition of absinthe was written into the Swiss constitution. In 1906, Belgium and Brazil banned the sale and distribution of absinthe although these were not the first countries to take such action. It had been banned as early as 1898 in the colony of the Congo Free State. The Netherlands banned it in 1909, Switzerland in 1910, the United States in 1912, and France in 1914. The prohibition of absinthe in France eventually led to the popularity of pastis, and to a lesser extent, ouzo, and other anise-flavoured spirits that do not contain wormwood.
=== Feeding === Polyps feed on a variety of small organisms, from microscopic zooplankton to small fish. The polyp's tentacles immobilize or kill prey using stinging cells called cnidocytes, commonly called nematocysts. These cells carry venom which they rapidly release in response to contact with another organism. A dormant nematocyst discharges in response to nearby prey touching the trigger. A stiff flap called an operculum opens and its stinging apparatus fires the barb into the prey. The venom is injected through the hollow filament to immobilise the prey; the tentacles then manoeuvre the prey into the stomach. Once the prey is digested the stomach reopens allowing the elimination of waste products and the beginning of the next hunting cycle.
== Strength == The strength of the adhesion between two materials depends on which of the above mechanisms occur between the two materials, and the surface area over which the two materials contact. Materials that wet against each other tend to have a larger contact area than those that do not. Wetting depends on the surface energy of the materials. Low surface energy materials such as polyethylene, polypropylene, polytetrafluoroethylene and polyoxymethylene are difficult to bond without special surface preparation. Another factor determining the strength of an adhesive contact is its shape. Adhesive contacts of complex shape begin to detach at the "edges" of the contact area. The process of destruction of adhesive contacts can be seen in the film. Recent experimental work has shown that adhesion-force measurements often exhibit non-Gaussian variability, and in some cases the normalized force distribution can be accurately represented using a Beta distribution.
Sources: en.wikipedia.org
=== Mechanism of action === The important interaction between phosphate and magnesium ions makes magnesium essential to the basic nucleic acid chemistry of all cells of all known living organisms. More than 300 enzymes require magnesium ions for their catalytic action, including all enzymes using or synthesizing ATP and those that use other nucleotides to synthesize DNA and RNA. The ATP molecule is normally found in a chelate with a magnesium ion.
lack of initial CSF pleocytosis (i.e. low CSF white blood cell count); elevated C-reactive protein; failure to sterilize the CSF before immune recovery. IRIS may be the cause of paradoxically worse outcomes for cryptococcal meningitis in immunocompetent compared with immunocompromised hosts, in whom Cryptococcus neoformans is the usual pathogen. Treatment with systemic corticosteroids during IRIS may be beneficial in preventing death or progressive neurological deterioration. Steroids given to persons with anti-fungal treatment failure / cryptococcal relapse (in whom CSF cultures are not sterile) can be a fatal iatrogenic error.
"Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. "Coronavirus disease (COVID-19) Pandemic". World Health Organization (WHO). "SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Sequences". National Center for Biotechnology Information (NCBI). "COVID-19 Resource Centre". The Lancet. "Coronavirus (Covid-19)". The New England Journal of Medicine. "Covid-19: Novel Coronavirus Outbreak". Wiley. Archived from the original on 24 September 2020. Retrieved 13 February 2020. "SARS-CoV-2". Virus Pathogen Database and Analysis Resource. "SARS-CoV-2 related protein structures". Protein Data Bank.
The Safety of Rwanda (Asylum and Immigration) Bill passes its third reading in the House of Commons with MPs voting 320–276 in favour of the bill. 18 January The UK Statistics Authority rebukes the prime minister for misleading the public over the backlog of asylum applications, which he said in a social media post had been cleared, while several thousand still remained. The UKSA says the allegation could have affected public trust in the government. A newborn girl is found in a shopping bag in Newham, London. It is thought that she was less than an hour old when she was found. The legal deadline to form a Northern Ireland Executive. On the same day, over 150,000 public sector workers stage a general strike across Northern Ireland. 19 January The Met Office issues a warning for high winds and heavy rain ahead of the arrival of Storm Isha. Tata Steel confirms it is cutting 2,800 jobs. It will close its blast furnaces at Port Talbot and replace them with an electric arc furnace, which produces less CO2 but requires fewer workers. The bodies of four people are found at a house in Costessey, near Norwich. All four people are believed to have been known to each other. Prince Harry withdraws his libel claim against Associated Newspapers, publisher of the Mail on Sunday, over an article concerning his security arrangements during a visit to the UK. A senior civil servant at the Department for Work and Pensions tells MPs that the UK government has stopped suspending Universal Credit claims flagged up as suspicious by an artificial intelligence fraud detector.
Analogues of 2C-T-36 (2C-T-TFM) include 2C-T-21 (2C-T-FE), 2C-T-21.5 (2C-T-DFE), 2C-T-22 (2C-T-TFE), 2C-T-28 (2C-T-FP), 2C-T-35 (2C-T-DFM), 2C-T, 2C-TFM, and 2C-TFE, among others. Some other analogues include 2C-Se-TFM, trifluoromescaline (TFM), 3C-TFE (3C-trifluoroescaline), and tiflorex (flutiorex). A deuterated isotopologue, CYB2108D (2C-T-36 with fully deuterated methoxy groups at 2 and 5 positions), is known.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.